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introduction
alzheimer’s disease (ad) is a progressive,
neurodegenerative disorder characterized by memory loss,
cognitive deterioration, executive and visuospatial dysfunction
and impaired ability to perform activities of daily living (1).
synaptic loss is thought to be a primary cause of the symptoms
of ad (2, 3), particularly hippocampal and cortical synapse
loss, as indicated by the nature of the cognitive dysfunction
typical of the disorder (3). 
Preclinical studies have indicated that the administration of
nutrients involved in the synthesis of synaptic membranes
increases synapse and synaptic membrane formation in the
brain. these include precursors for membrane
phosphatidylation such as uridine, choline and omega-3
polyunsaturated fatty acids (4-6). Reports have also indicated
that combining these nutrients may improve cognition and
increase hippocampal dendritic spines (7), again suggesting a
positive effect on the formation of new synapses (8-10). it was
therefore hypothesized that such agents may play a role in the
management of ad.
this hypothesis led to the development of the medical food
souvenaid® (Nutricia N.V., Zoetermeer, the Netherlands) (11),
a multinutrient drink designed to provide the precursor and
supporting nutrients that may enhance synaptic membrane
formation and function in patients with ad. a recent proof-of-
concept study demonstrated that dietary supplementation with
souvenaid was well tolerated, and resulted in a significant
improvement of memory, as measured by 12-week delayed
verbal recall testing (12). the co-primary outcome measure for
the study, the modified 13-item alzheimer’s disease
assessment scale – cognitive subscale (adas-cog) (13)
showed no overall intervention effect for souvenaid, with
neither the control nor active group showing any decline over
24 weeks on this outcome measure, which was attributed to a
potential lack of sensitivity with the adas-cog measure in
mild ad patients over this study period (12). adas-cog is
widely regarded by regulatory authorities as the ‘gold standard’
outcome measure for assessing cognitive change in clinical
trials, and as such it is important to further investigate factors
that might influence the effect on adas-cog. this formed the
rationale for investigating the extent that baseline cognitive
impairment affected the adas-cog intervention response. in
addition, we studied the influence of intake adherence on
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adas-cog response.
materials and methods
Study design
the 24-week proof-of-concept study (12) consisted of a 
12-week, double-blind, randomized, controlled, multicenter
trial, followed by a similarly designed, optional 12-week
extension study, to evaluate the effect of souvenaid® on
cognitive function in patients with mild ad. the methodology
has been described in detail previously (12). in summary,
patients ≥50 years of age with a diagnosis of probable ad and a
mini-mental state examination (mmse) score of 20–26 were
recruited. Patients were randomized to receive either active or
control product as a 125 ml daily drink. Primary outcome
measures were a delayed verbal recall task (Wms-r) (14) and
adas-cog (13-item version, range 0–85, higher scores
indicating greater cognitive deficit) (13) measures of delayed
verbal memory and cognition. these parameters were measured
at baseline and at Weeks 6, 12 and 24. adherence to study
product intake was measured via patient documentation of the
amount of study product taken each day and verified by
measuring blood plasma parameters. the study was conducted
in accordance with the declaration of Helsinki and the
international conference on Harmonisation of technical
Requirements for Registration of Pharmaceuticals for Human
use / WHO Good clinical Practice (icH-GcP) guidelines, as
appropriate to nutritional products and legislation of the country
in which the research was conducted. the clinical trial
registration number is isRctN72254645. 
Modeling analysis
the primary analysis population was the intention-to-treat
(itt) efficacy population from the proof-of-concept study,
defined as all randomized patients who received at least one
dose of study product and one post-baseline assessment. For the
modeling analyses presented here, one patient (from the active
study group) was excluded from the itt efficacy population as
he showed an extreme outlying response on the 24-week
adas-cog outcome (Figure 1). this may be explained by a leg
amputation 8 days prior to the 24-week adas-cog assessment,
which took place in the hospital and was recorded as a serious
adverse event. Based on the median as a cut-off value, the study
population was divided into two subgroups: patients with ‘low’
baseline adas-cog scores (<25.0; lower scores indicating
reduced cognitive deficit) and patients with ‘high’ baseline
adas-cog scores (≥25.0; indicating greater cognitive deficit). 
Repeated measures models (Rmm) for each subject were
used to determine the relationship between adas-cog score
and intervention up to 24 weeks. the sas procedure PROc
miXed (15) was used to model the covariance among the
repeated measures obtained on the same individuals (16).
different structures for the means and different
variance–covariance structures were tested. the structure with
the best fit was selected based on the likelihood ratio test for
nested models and the akaike information criterion (aic) for
non-nested models.
figure 1
a quantile-quantile (Q-Q)-plot to show individual patient data
variations (adas-cog) from the normal distribution. One
extreme case (circled) with various co-morbidities was shown
to deviate considerably and was excluded from the modeling
analyses
results
Overall, 225 patients were randomized: 112 to active product
and 113 to the control product. Of these, 161 completed the 
24-week study (12). Baseline characteristics for the control and
active patient populations in the current analysis are reported
for all subjects, together with those for the ‘high’ and ‘low’
baseline adas-cog subgroups (table 1). there were no
statistically significant differences in baseline characteristics
between active/control groups (table 1).
table 1
Patient characteristics at baseline
characteristic randomized study group
control product active product
total patient population (n = 106) (n = 105)
men, n (%) 52 (49) 53 (50)
age ± sd, yr 73.3 ± 7.8 74.1 ± 7.3
13-item adas-cog, mean ± sd 25.5 ± 8.8 25.9 ± 7.6
mmse, mean ± sd 24.0 ± 2.5 23.9 ± 2.7
‘low’ baseline adas-cog group (n = 43) (n = 52)
men, n (%) 25 (58) 35 (67)
age ± sd, yr 71.4 ± 8.4 73.6 ± 6.9
13-item adas-cog, mean ± sd 17.6 ± 5.4 19.8 ± 3.2
mmse, mean ± sd 25.3 ± 2.1 25.0 ± 2.1
‘High’ baseline adas-cog group (n = 63) (n = 53)
men, n (%) 27 (43) 18 (34)
age ± sd, yr 74.6 ± 7.0 74.5 ± 7.7
13-item adas-cog, mean ± sd 30.9 ± 6.3 31.9 ± 5.7
mmse, mean ± sd 23.1 ± 2.4 22.7 ± 2.7
all patients included in the modeling analysis: intention-to-treat efficacy population (12)
minus one outlier; adas-cog = alzheimer’s disease assessment scale – cognitive
subscale (0–85; higher scores indicate greater cognitive dysfunction); mmse = mini-
mental state examination (0–30; lower scores indicate greater cognitive dysfunction).
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Subgroup of patients with ‘high’ baseline ADAS-cog
Raw mean adas-cog scores for patients with ‘high’
baseline adas-cog are summarized in table 2 (at baseline and
Weeks 6, 12 and 24). Within this subgroup the adas-cog data
were substantially skewed and a transformation was performed
to adjust for this. 
table 2
Raw mean (± sd) adas-cog scores for the patient subgroups
‘low’ baseline adas-cog group ‘high baseline adas-cog group
n control n active n control n active
Baseline 43 17.6 ± 5.4 52 19.8 ± 3.2 63 30.9 ± 6.3 53 31.9 ± 5.7
Week 6 41 18.2 ± 5.9 51 20.6 ± 4.8 61 29.5 ± 6.9 48 30.5 ± 8.1
Week 12 39 19.3 ± 6.0 51 21.6 ± 5.6 60 30.1 ± 5.7 50 30.3 ± 7.1
Week 24 34 17.4 ± 5.8 44 20.7 ± 6.1 45 30.1 ± 5.9 38 29.8 ± 8.4
all patients included in the modeling analysis: intention-to-treat efficacy population (12)
minus one outlier; adas-cog = alzheimer’s disease assessment scale – cognitive
subscale (0–85; higher scores indicate greater cognitive dysfunction). 
Rmm slope analysis of the transformed adas-cog, using
adas-cog at baseline, 6, 12 and 24 weeks as the dependent
variable, showed a significant treatment effect (F[1,319] = 4.0,
p = 0.046). sensitivity analyses showed a strong indication (all
p-values ranging from 0.029–0.067) that this effect is
independent of: (a) the type of structure for the means used
(modeling each visit separately using dummy variables instead
of modeling the means as a straight-line and evaluating slopes);
(b) the type of variance–covariance model used (compound
symmetry instead of heterogeneous compound symmetry); and
(c) the type of adas-cog transformation used (logarithm
instead of square-root). Figure 2 shows the results from the
Rmm analyses (estimated means) for adas-cog over 24
weeks for patients with ‘high’ baseline adas-cog scores. the
clear upward slope (representing a decrease in adas-cog
score and indicating cognitive improvement) for the active
group contrasts with the almost unchanged level of the control
group. these data indicate that souvenaid significantly
improved cognitive performance versus the control product in
patients with ‘high’ baseline adas-cog. 
Subgroup of patients with ‘low’ baseline ADAS-cog
Raw mean adas-cog scores for patients with ‘low’
baseline adas-cog are summarized in table 2 (at baseline and
Weeks 6, 12 and 24). Within this subgroup there was no
suggestion of an intervention effect, indicated by a non-
significant intervention*time parameter (F[1,250] = 1.25, 
p = 0.265). 
Baseline ADAS-cog value as a predictor of ADAS-cog
change from baseline
in order to determine whether the two adas-cog subgroups
significantly differed from each other, they were combined into
a single model. a patients’ membership to either subgroup was
found to be a significant predictor of adas-cog intervention
response (Rmm: F[1,657] = 3.94, p = 0.048 for the
subgroup*slope coefficient, using untransformed adas-cog
and allowing for different heterogeneous compound symmetry
variance–covariance matrices for subgroups).
figure 2
estimated marginal mean adas-cog scores over 24 weeks for
patients receiving active or control product who recorded a
‘high’ (≥median) adas-cog score at baseline (back-
transformed data; transformed [square-root] data were squared)
figure 3
scatter-plot of individual patient adas-cog change from
baseline (24-week, non-transformed) by intake adherence
(percentage of prescribed product taken), for both active and
control groups. Regression lines are included for each
intervention group
Impact of intake adherence on intervention response
the relationship between intake adherence (represented as a
percentage of the total study product consumed by the patient)
and 24-week adas-cog change is shown in Figure 3. the
active group showed a significant correlation between intake
adherence and adas-cog improvement (correlation coefficient
= -0.260; p = 0.019), but this correlation was not observed in
the control group (correlation coefficient = 0.108, p = 0.343).
this difference in correlation coefficients between the active
and control group was statistically significant (Fisher’s Z
transformation, Z = 2.32, p = 0.020). effect modifier analyses
to determine the relationship between intake adherence and
adas-cog response showed a significant interaction 
(F[1,546] = 5.88, p = 0.016; Rmm model using untransformed
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adas-cog and including variable “intake adherence”).
in summary, together with the incidence of adverse events
(12), baseline adas-cog and intake adherence appear to be
important effect modifiers that can influence the 24-week
adas-cog intervention effect. 
discussion
this post-hoc analysis indicates that baseline adas-cog
score significantly influenced the effect of souvenaid
intervention on this outcome measure. Within the group of
patients with higher adas-cog scores at baseline, souvenaid
significantly improved adas-cog scores compared with the
control group. these observations are in line with recent
publications that bring into question the sensitivity of adas-
cog in mild cognitive impairment and mild ad (17-19). this
may be due to the poor psychometric properties of the adas-
cog measure, such as inadequate assessment of cognitive
domains such as attention, working memory and executive
function (19, 20) and the presence of floor effects (17).
Furthermore, several recent studies have reported slower rates
of placebo decline in ad patients than traditionally assumed by
older models and clinical trials (12, 21-23); they have also
shown that baseline adas-cog significantly affects the rate of
ad progression (23, 24). 
most ad intervention studies report on a mild–moderate
dementia population. Only a few prospective intervention
studies have been performed in an exclusively mild ad
population using adas-cog as an outcome measure (25-28).
Of these, only the study reported by seltzer et al. (25) reported
a significant benefit on adas-cog. 
in the study reported here, an absolute difference in adas-
cog score between study groups of 2 points was demonstrated
in favor of the active intervention group, for patients with
higher adas-cog at baseline. this subgroup represents
patients at a more advanced stage within the mild ad study
population. this effect was observed despite the small sample
size of this subgroup. However, it should also be noted that the
statistical phenomenon of linear regression to the mean may
have contributed to the apparent treatment effect.
the clinical importance of adas-cog change has been
reviewed in several recent publications (22, 29). Vellas et al.
reported that a 2-point effect on adas-cog outcome at 
18 months may be considered clinically relevant, but greater
differences (3–4 points) for clinical relevance have also been
proposed (30). taking these suggestions into account, the 
2-point adas-cog intervention difference (13-item scale,
range 0–85) may be considered a relevant finding that warrants
further investigation in patients at a more advanced stage of
ad. 
Within the active study group a significant correlation
between intake adherence and adas-cog improvement was
observed. this indicates that a higher intake of souvenaid (up
to and including the prescribed dosage) provides greater
cognitive benefit in ad patients up to 24 weeks. as expected,
this relationship was not observed in the control group. in the
study, excellent intake adherence was also demonstrated: the
average 24-week compliance was 94% (percentage product
intake versus prescribed dosage). these results, combined with
the finding that intake adherence appears positively correlated
to adas-cog improvement, highlight the potential of
souvenaid in ad.
thus, although adas-cog is still considered the ‘gold
standard’ measure of cognitive function in clinical trials for ad
and other dementias, in modern studies it may be unable to
detect subtle changes in patients with milder stages of the
disease (18). to account for this issue, an ongoing study to
investigate the efficacy of souvenaid in ad with adas-cog as
the primary outcome measure (s-cONNect; NtR1683)
includes patients with more moderate cognitive dysfunction
(mmse 14–24) than the original study (mmse 20–26).
certainly, in the current analysis when the subgroup of ad
patients with ‘high’ adas-cog scores at baseline was analyzed
using Rmm, the data showed that souvenaid provided
beneficial effects compared with control for up to 24 weeks. in
addition, the results of this analysis indicate that adverse events,
baseline cognitive severity and intake adherence should be
taken into account when designing, and interpreting the results
of, future studies.
in conclusion, the results of a controlled, 24-week, proof-of-
concept study demonstrated that dietary supplementation with
souvenaid yields improvements in the memory of patients with
mild and very mild ad (12). the analysis presented here also
suggests that souvenaid may provide cognitive benefits to
patients with more moderate stages of the disease. these
hypothesis-generating results warrant confirmation in larger
scale, controlled studies. 
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